Almonertinib in the First-line Treatment of Patients of NSCLC With Poor Performance Status
Status:
Recruiting
Trial end date:
2024-12-30
Target enrollment:
Participant gender:
Summary
Most of the lung cancer patients treated in hospitals in China are in advanced stage,
accounting for more than 2/3 of all lung cancer patients, and some of the patients have a
poor performence status.At present, most of the patients included in clinical trials are
patients with good PS score, and the NCCN guidelines for advanced lung cancer patients with
poor performence status recommend the best supportive care.Therefore, the investigator wanted
to explore the efficacy and safety of Almonertinib in lung cancer patients with poor
performance status.